233 related articles for article (PubMed ID: 20448669)
21. Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs.
Pearson JD; Zhang J; Wu Z; Thew KD; Rowe KJ; Bacani JT; Ingham RJ
Mol Cancer; 2014 Aug; 13():199. PubMed ID: 25168906
[TBL] [Abstract][Full Text] [Related]
22. The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma.
Wang P; Zhang JD; Wu F; Ye X; Sharon D; Hitt M; McMullen TP; Hegazy SA; Gelebart P; Yang J; Ma Y; Lai R
Cell Signal; 2012 Oct; 24(10):1955-63. PubMed ID: 22743134
[TBL] [Abstract][Full Text] [Related]
23. The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines.
Carnesecchi S; Rougemont AL; Doroshow JH; Nagy M; Mouche S; Gumy-Pause F; Szanto I
Free Radic Biol Med; 2015 Jul; 84():22-29. PubMed ID: 25797883
[TBL] [Abstract][Full Text] [Related]
24. Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.
Mastini C; Campisi M; Patrucco E; Mura G; Ferreira A; Costa C; Ambrogio C; Germena G; Martinengo C; Peola S; Mota I; Vissio E; Molinaro L; Arigoni M; Olivero M; Calogero R; Prokoph N; Tabbò F; Shoji B; Brugieres L; Geoerger B; Turner SD; Cuesta-Mateos C; D'Aliberti D; Mologni L; Piazza R; Gambacorti-Passerini C; Inghirami GG; Chiono V; Kamm RD; Hirsch E; Koch R; Weinstock DM; Aster JC; Voena C; Chiarle R
Sci Transl Med; 2023 Jun; 15(702):eabo3826. PubMed ID: 37379367
[TBL] [Abstract][Full Text] [Related]
25. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
Riera L; Lasorsa E; Ambrogio C; Surrenti N; Voena C; Chiarle R
J Biol Chem; 2010 Aug; 285(34):26441-50. PubMed ID: 20554525
[TBL] [Abstract][Full Text] [Related]
26. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.
Ambrogio C; Voena C; Manazza AD; Martinengo C; Costa C; Kirchhausen T; Hirsch E; Inghirami G; Chiarle R
Cancer Res; 2008 Nov; 68(21):8899-907. PubMed ID: 18974134
[TBL] [Abstract][Full Text] [Related]
27. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.
Dien Bard J; Gelebart P; Anand M; Zak Z; Hegazy SA; Amin HM; Lai R
Am J Pathol; 2009 Aug; 175(2):825-34. PubMed ID: 19608866
[TBL] [Abstract][Full Text] [Related]
28. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression.
Desjobert C; Renalier MH; Bergalet J; Dejean E; Joseph N; Kruczynski A; Soulier J; Espinos E; Meggetto F; Cavaillé J; Delsol G; Lamant L
Blood; 2011 Jun; 117(24):6627-37. PubMed ID: 21471522
[TBL] [Abstract][Full Text] [Related]
29. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
[TBL] [Abstract][Full Text] [Related]
30. ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.
Martinengo C; Poggio T; Menotti M; Scalzo MS; Mastini C; Ambrogio C; Pellegrino E; Riera L; Piva R; Ribatti D; Pastorino F; Perri P; Ponzoni M; Wang Q; Voena C; Chiarle R
Cancer Res; 2014 Nov; 74(21):6094-106. PubMed ID: 25193384
[TBL] [Abstract][Full Text] [Related]
31. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
Staber PB; Vesely P; Haq N; Ott RG; Funato K; Bambach I; Fuchs C; Schauer S; Linkesch W; Hrzenjak A; Dirks WG; Sexl V; Bergler H; Kadin ME; Sternberg DW; Kenner L; Hoefler G
Blood; 2007 Nov; 110(9):3374-83. PubMed ID: 17690253
[TBL] [Abstract][Full Text] [Related]
32. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes.
Lamant L; de Reyniès A; Duplantier MM; Rickman DS; Sabourdy F; Giuriato S; Brugières L; Gaulard P; Espinos E; Delsol G
Blood; 2007 Mar; 109(5):2156-64. PubMed ID: 17077326
[TBL] [Abstract][Full Text] [Related]
33. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells.
Wan W; Albom MS; Lu L; Quail MR; Becknell NC; Weinberg LR; Reddy DR; Holskin BP; Angeles TS; Underiner TL; Meyer SL; Hudkins RL; Dorsey BD; Ator MA; Ruggeri BA; Cheng M
Blood; 2006 Feb; 107(4):1617-23. PubMed ID: 16254137
[TBL] [Abstract][Full Text] [Related]
34. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
35. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
36. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.
Atsaves V; Lekakis L; Drakos E; Leventaki V; Ghaderi M; Baltatzis GE; Chioureas D; Jones D; Feretzaki M; Liakou C; Panayiotidis P; Gorgoulis V; Patsouris E; Medeiros LJ; Claret FX; Rassidakis GZ
Br J Haematol; 2014 Nov; 167(4):514-23. PubMed ID: 25145835
[TBL] [Abstract][Full Text] [Related]
37. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.
Kim D; Koh Y; Yoon SS
Anticancer Res; 2020 Mar; 40(3):1395-1403. PubMed ID: 32132036
[TBL] [Abstract][Full Text] [Related]
38. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.
Hoareau-Aveilla C; Valentin T; Daugrois C; Quelen C; Mitou G; Quentin S; Jia J; Spicuglia S; Ferrier P; Ceccon M; Giuriato S; Gambacorti-Passerini C; Brousset P; Lamant L; Meggetto F
J Clin Invest; 2015 Sep; 125(9):3505-18. PubMed ID: 26258416
[TBL] [Abstract][Full Text] [Related]
39. Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.
Wu F; Wang P; Zhang J; Young LC; Lai R; Li L
Mol Cell Proteomics; 2010 Jul; 9(7):1616-32. PubMed ID: 20393185
[TBL] [Abstract][Full Text] [Related]
40. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
